Editing Postpartum depression (section)

=== Breastfeeding ===
The use of SSRIs for the treatment of PPD is not a contraindication for breastfeeding. While antidepressants are excreted in breastmilk, the concentrations recorded in breastmilk are very low.<ref name=":1">{{cite journal | vauthors = Berle JO, Spigset O | title = Antidepressant Use During Breastfeeding | journal = Current Women's Health Reviews | volume = 7 | issue = 1 | pages = 28–34 | date = February 2011 | pmid = 22299006 | pmc = 3267169 | doi = 10.2174/157340411794474784 }}</ref><ref name=":2">{{cite journal | vauthors = Weisskopf E, Fischer CJ, Bickle Graz M, Morisod Harari M, Tolsa JF, Claris O, Vial Y, Eap CB, Csajka C, Panchaud A | title = Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence | journal = Expert Opinion on Drug Safety | volume = 14 | issue = 3 | pages = 413–427 | date = March 2015 | pmid = 25554364 | doi = 10.1517/14740338.2015.997708 }}</ref> Extensive research has shown that the use of SSRI's by women who are lactating is safe for the breastfeeding infant/child.<ref name=":1" /><ref name=":2" /><ref>{{cite journal | vauthors = Hallberg P, Sjöblom V | title = The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects | journal = Journal of Clinical Psychopharmacology | volume = 25 | issue = 1 | pages = 59–73 | date = February 2005 | pmid = 15643101 | doi = 10.1097/01.jcp.0000150228.61501.e4 }}</ref> Regarding allopregnanolone, very limited data did not indicate a risk for the infant.<ref>{{cite web |title=FDA Prescribing Information for Brexanolone |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf |access-date=23 March 2019}}</ref>